Study design and intervention
Alzheimer’s Disease Assessment Scale
This was an open-label, single-arm clinical trial that received institutional approval from the Ethics Review Board of the Affiliated Hospital of Guangdong Medical University (PJ2020-110) and was conducted in accordance with the Helsinki statement. All patients provided informed consent. If the patient was eligible, they took fecal microbiota capsules three times. Before use, the device was incubated at 37°C for 10 min and then placed at room temperature for 10 min. The patients fasted 6 hours before and 1 hour after FMT. FMT was taken within 3 hours, with a total of 40 pills per intake. Patients were required to return to the hospital for FMT every other week. Indicators of cognitive ability, including Activities of Daily Living (ADL), the Montreal Cognitive Assessment-B (MoCA-B), and the cognitive section of the Alzheimer’s Disease Assessment Scale (ADAS-Cog) were assessed at days 0, 30, 60, 90, and 180. Fecal and serum samples were also collected at days 0 and 180.